Gilead to acquire CymaBay for $4.3B, gaining liver disease drug

Taking stock of the drug industry, from the lab to the medicine chest

February 12, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Yichuan Cao/Sipa USA STAT+ | Gilead to acquire CymaBay for $4.3 billion, adding new treatment for liver disease CymaBay's drug is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women. By Adam Feuerstein Ebola vaccine cuts fatality even in people who were infected before the jab, new study shows People vaccinated against Ebola who still developed the disease had a substantially lower risk of dying, a new study shows. By Helen Branswell STAT+ | FTC doubles down in Welsh Carson anesthesia case to limit private equity's physician buyouts The FTC is pushing back hard on private equity firm Welsh, Carson, Anderson & Stowe and U.S. Anesthesia Partners for rolling up anestheisa practices. By Bob Herman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser